retatrutide clinical trials sign up A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide Starting Dose: What Clinical

Helpful Tools Related Articles Retatrutide Availability & Timeline Retatrutide is expected to receive FDA approval in mid-2027 with pharmacy availability in late 2027

Some research peptide vendors provide third-party certificates of analysis (COA) showing purity testing

It mimics a gut hormone responsible which binds to the GLP-1 receptor for regulating blood sugar levels and your perception of hunger, in effect suppressing your appetite

Both require a prescription and are covered by many insurance plans

Lilly spokesperson Niki Biro cautioned that retatrutide is an investigational molecule that is legally available only to participants in Lillys clinical trials

Lilly usually offers savings cards that can drop the cost significantly